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ABSTRACT 
This study reports the antibiotic susceptibility and genetic resistance determinants of 39 
Clostridium butyricum strains isolated from the faeces of preterm infants as well as one 
reference strain. Results showed that all the strains were susceptible to cefoxitin, 
imipenem, vancomycin, tigecycline, metronidazole, chloramphenicol and linezolid. 
Resistance was observed to clindamycin (100%), penicillin G, amoxicillin and piperacillin 
(15%), tetracycline (7.5%) and erythromycin (5%). Investigation of the genetic basis of the 
observed resistance phenotypes showed that resistance to penicillin was due to -
lactamase activity and that resistance to tetracycline involved tet(O) or tet(O/32/O) 
homologue genes. Clindamycin and erythromycin resistance may involve another genetic 
determinant, different from those commonly described for clostridia. 
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1. Introduction 
Preterm infants have delayed bacterial colonisation compared with full-term infants, 
leading to microbiota imbalance with overgrowth of potentially pathogenic bacteria. This 
dysbiosis is a risk factor for the onset of gastrointestinal diseases in this target population 
[1]. For instance, compared with term infants, premature infants at risk of necrotizing 
enterocolitis (NEC) have a paucity of bacterial species and/or delayed onset of bacterial 
gut colonisation [2].  
 
Clostridia are among the anaerobes that are part of the indigenous intestinal microbiota of 
humans. These commensal spore-forming Gram-positive rods belong to the species 
isolated from the normal neonatal gut bacterial community of full-term [3] and preterm 
infants [4,5]. In preterm infant gut microbiota, occurrences of clostridia, in particular 
Clostridium butyricum, have been described [4,5]. Clostridial colonisation has been linked 
to a higher risk of NEC [6], a devastating gastrointestinal disease with high morbidity and 
mortality, and several investigations have supported the role of clostridial species in NEC 
pathogenesis [6–10], although other bacterial species have also been implicated [1,11]. 
Indeed, high production of metabolites through colonic bacterial fermentation is thought to 
be responsible for the onset of digestive lesions, i.e. gas cysts, haemorrhagic lesions and 
necrosis, as shown in animal models of NEC [11–13]. Despite the similarities of NEC to 
clostridial infection, only a few studies have employed anaerobic culture techniques for 
isolation, identification and characterisation of clostridial strains routinely. Little information 
is therefore available on this species. In particular, data on its susceptibility to antibiotics 
are very scarce and relate to few strains, although perinatal antibiotic treatment is very 
frequent in preterm infants. The aim of this study was to perform and report the first 
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survey of the antimicrobial susceptibility patterns and genetic resistance determinants of 
C. butyricum isolated from preterm infant faeces. 
 
2. Material and methods 
2.1. Isolates and strain identification 
Among 102 premature infants screened from four different French hospitals, 39 C. 
butyricum strains were isolated (from 2004 to 2009). Among the 39 strains, 3 were 
isolated from three different neonates with NEC from the different hospitals. 
 
Strain isolation was as performed as follows. Faecal samples were crushed in brain–
hearth infusion broth using an Ultra-Turrax T25 (Fisher-Bioblock, Illkirch, France) and 
diluted in peptone water and then 10–2, 10–4 and 10–6 dilutions were spread using a WASP 
apparatus (AES Chemunex, Bruz, France) on clostridia sulphite–polymyxin–milk selective 
medium and incubated for 48 h at 37 C in an anaerobic chamber (AES Chemunex) under 
anaerobic gas phase (H2:CO2:N2, 10:10:80, v/v/v). Colonies suspected as being clostridia 
on the basis of cellular morphology and Gram staining were identified using Rapid ID 32A 
strips (bioMérieux, Marcy l’Etoile, France). Identification was confirmed by partial 
sequencing of the 16S rRNA gene, which was amplified by polymerase chain reaction 
(PCR) using primers LPW58 (5’-AGGCCCGGGAACGTATTCAC-3’) and LPW81 (5’-
TGGCGAACGGGTGAGTAA-3’). Reference strain C. butyricum ATCC 19398 was 
included in the study. Liquid cultures were performed in TGYH broth (tryptone 30 g/L, 
glucose 5 g/L, yeast extract 20 g/L and hemin 5 mg/L) for 24 h at 37 C in an anaerobic 
chamber (AES Chemunex). 
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2.2. Minimal inhibitory concentration (MIC) determination 
MICs for penicillin G, amoxicillin, cefoxitin, piperacillin, imipenem, vancomycin, 
tetracycline, tigecycline, erythromycin, clindamycin, ofloxacin, metronidazole, 
chloramphenicol and linezolid were determined using the agar dilution method on Brucella 
agar medium supplemented with 0.5% sheep blood. An inoculum was prepared for each 
strain by suspending cells from a plate in TGYH broth to achieve a turbidity equivalent to 
that of a 0.5 McFarland standard (3  105 cells/mL) and the inoculum was delivered by a 
Steers replicator onto agar plates. Resistant and susceptible strains were characterised 
following Clinical and Laboratory Standards Institute (CLSI) breakpoints [14]. 
 
2.3. PCR amplifications 
Purified genomic DNA of all 40 strains (39 clinical strains and 1 reference strain) was used 
as a template for PCR amplification of the protection ribosomal genes tet(M), tet(W), 
tet(O) and tet(Q), the efflux pump genes tet(K) and tet(L), and the C. butyricum 
chromosomal efflux pump tet(P) (GenBank accession no. EDT76835.1), rRNA methylases 
genes erm(B), erm(Q) and erm(F), and lmrB (accession number no. EDT76011) (Table 1). 
The PCR mixture was composed of 1 M of each primer, 5% dimethyl sulphoxide 
(DMSO), each deoxynucleotide triphosphate (dNTP) at a concentration of 250 M in 1 
PCR buffer and 1.25 U of recombinant DNA polymerase (Invitrogen, Illkirch, France) in a 
final volume of 25 L. The PCR programme was 4 min at 95 C, followed by 30 cycles of 
30 s at 94 C, 30 s at 50 C and 90 s at 72 C, and a 5 min final extension at 72 C. When 
PCR products where obtained for tet, erm or lmrB genes they were sequenced to confirm 
their identity (Genome Express SA, Meylan, France). Sequences were analysed using the 
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BLAST Align program available from the National Center for Biotechnology Information 
(NCBI). 
 
2.4. tet(P) and lmrB reverse transcription polymerase chain reaction (RT-PCR) 
After 16 h of growth in TGYH broth, 0.5 mL of bacterial culture was mixed with 1 mL of 
RNAprotect (QIAGEN, Courtaboeuf, France). Total RNA was isolated using an RNeasy 
Mini Kit (QIAGEN). Following extraction, DNA contamination was removed by RNase-free 
DNase (QIAGEN) digestion for 30 min at 37 C. Total RNA concentration and purity were 
determined using a NanoDrop® ND-1000 spectrophotometer (Thermo Fisher Scientific, 
Villebon-sur-Yvette, France) and total RNA was stored at –80 C. RT-PCR was performed 
using a SuperScript® III RT Kit (Invitrogen) with 1 g of total RNA. The primer pairs TetP-
ShrtF/TetP-ShrtR and LmrB-ShrtF/LmrB-ShrtR (Table 1) were used for cDNA 
amplification. The C. butyricum housekeeping gene recA (accession no. EDT76977) was 
used as a reference, and cDNA amplification was performed using primers RecA-F/RecA-
R (Table 1). One microlitre of the resulting cDNA was amplified with tet(P) and lmrB 
primers (Table 1). 
 
2.5. Nucleotide sequence accession numbers 
Nucleotide sequences of the potential tet(O/32/O) gene homologue and tet(O) genes were 
deposited in the GenBank database under the accession nos. GQ240299, GQ240297 and 
GQ240298, respectively. 
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3. Results and discussion 
3.1. Susceptibility levels 
Non-perfringens Clostridium spp. have been reported to be susceptible to penicillins, 
imipenem and metronidazole, whereas resistance occurred to cefoxitin and clindamycin 
[15,16]. With regard to C. butyricum, no comparative data were available because its 
susceptibility levels were included among the Clostridium spp. group. In this study, out of 
the 40 C. butyricum strains tested, all were susceptible to vancomycin (MICs ≤ 4 mg/L), 
imipenem (MICs ≤ 2 mg/L), tigecycline (MICs ≤ 4 mg/L), linezolid (MICs < 4 mg/L), 
metronidazole (MICs ≤ 4 mg/L) and cefoxitin (MICs < 32 mg/L) (Table 2); strains were 
susceptible (MICs ≤ 1 mg/L) or intermediate (1 mg/L < MICs < 4 mg/L) to ofloxacin (Table 
2). Although chloramphenicol resistance has been reported for C. butyricum reference 
strains [17], in this study all the strains were susceptible (MICs ≤ 8 mg/L). Antibiotic 
resistance was observed to penicillin G (MICs > 8 mg/L), amoxicillin (MICs > 8 mg/L) and 
piperacillin (MICs > 16 mg/L) for six strains, to tetracycline for three strains (MICs > 8 
mg/L), to clindamycin for all strains (MICs  8 mg/L) and to erythromycin for two strains 
(MICs = 256 mg/L) (Table 2). 
 
3.2. -Lactam resistance 
Most clostridia are susceptible to -lactam agents. However, some species, such as 
Clostridium difficile, are less susceptible [15]. -Lactamase production has been reported 
in only three species, namely C. butyricum, Clostridium clostridioforme and Clostridium 
ramosum [18], with no data on its incidence owing to the low number of strains tested. In 
this study, resistance to penicillin G (MICs > 8 mg/L), amoxicillin (MICs > 8 mg/L) and 
piperacillin (MICs > 16 mg/L) was observed for six strains (15%). Based on the nitrocefin 
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assay, all of the penicillin-resistant strains showed -lactamase activity. In addition, the -
lactamases were inhibited by clavulanic acid, which has been reported to be a particularity 
of C. butyricum [19]. 
 
3.3. Tetracycline resistance 
In this study, three C. butyricum strains showed resistance to tetracycline (MICs > 8 
mg/L). One of the mechanisms involved in tetracycline resistance among anaerobic 
bacteria is ribosomal protection. Among clostridia, tet(M) was the most frequently 
identified tetracycline resistance gene for C. difficile [20,21] and C. perfringens [22]; the 
tet(O) [21] and tet(W) [23] genes were less frequently reported. In this study, the genomic 
DNA of all strains was used as a template for PCR amplification of the tet(M), tet(W), 
tet(O) and tet(Q) genes. Using the degenerated primers tet1 and tet2, PCR results 
showed that the tet(M), tet(W) and tet(Q) genes were absent in all of the isolates tested. 
Of the three tetracycline-resistant strains (strains 2, 22 and 33), only strain 22 showed 
amplification of the expected 1250-bp PCR product. The same 1250-bp PCR product was 
amplified for two non-resistant strains (strains 51 and 52). The nucleotide sequence of the 
1250-bp fragment of strain 22 shared 71% identity with the mosaic tet(O/32/O) gene 
(accession no. AJ295238) from Clostridiaceae bacterium K10. Meanwhile, the nucleotide 
sequences of the same fragment for strains 51 and 52 showed 99% identity with tet(O) 
genes from Enterococcus faecalis (accession no. AY660532) and Campylobacter jejuni 
(accession no. M18896). To amplify the full-length genes of strains 22, 51 and 52, the 
primer combination OFF2/OFR3 was used (Table 1). This approach allowed the 
amplification of a 2000-bp PCR product with only the OFF2/OFR3 primers for strains 51 
and 52 but not for strain 22. After sequencing, the 2000-bp PCR product nucleotide 
sequences from strains 51 and 52 shared 99% identity with the already mentioned tet(O) 
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genes. Attempts to amplify the full-length gene for strain 22 using multiple primer 
combinations were unsuccessful (data not shown). 
 
To investigate the tetracycline resistance mechanism of strains 2 and 33, all strains were 
screened for the tet(P), tet(K) and tet(L) tetracycline efflux pumps genes. Indeed, such 
genes have been identified in C. difficile [24] and C. perfringens [25]. PCR screening 
showed that tet(K) and tet(L) were absent from all the strains tested. The tet(P) gene 
(accession no. EDT76835.1), which was found to be present on the C. butyricum 5521 
sequenced genome (accession no. NZ ABDT00000000), was identified for all strains 
except strains 22, 51 and 52. RT-PCR experiments confirmed tet(P) expression for 
tetracycline-resistant strains 2 and 33. However, tet(P) expression was also observed for 
all susceptible strains. The fact that tet(P) may be tightly regulated at the transcriptional or 
translational levels may explain these observations [26]. 
 
3.4. Erythromycin and clindamycin resistance 
Macrolide–lincosamide–streptogramin B (MLSB) resistance in clostridia is mostly encoded 
by rRNA methyltransferase erm genes. In C. difficile and C. perfringens it involves the 
erm(B), erm(Q) or erm(F) genes [21,25]. With regard to C. butyricum, one clinical isolate 
was reported to carry erm(B) and erm(F) genes [27]. In this study, all strains showed MICs 
 8 mg/L to clindamycin and two were resistant to erythromycin (MICs of 256 mg/L). PCR 
amplification for erm genes showed the absence of erm(B), erm(Q) and erm(F) as an 
explanation for the observed resistance (data not shown). Such observations have been 
reported for other erm-negative clostridia with erythromycin and clindamycin resistance 
[28]. These results suggest the presence of an alternative resistance mechanism(s). 
Interestingly, an lmrB efflux gene homologue (accession number no. EDT76011) was 
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found to be present on the C. butyricum 5521 sequenced genome (accession no. NZ 
ABDT00000000). Although efflux pumps may participate in clindamycin resistance in 
anaerobic bacteria [29], it was not reported for clostridia. In this study, PCR amplification 
of the chromosomal C. butyricum efflux gene homologue lmrB was positive for 70% of the 
strains. RT-PCR experiments showed that 75% of the lmrB-positive strains showed gene 
expression. This suggests the involvement of other mechanism(s) in the observed 
resistance. 
 
4. Conclusion 
This study provides recent information on the status of C. butyricum antimicrobial 
susceptibility and shows that this human gut commensal bacterium is susceptible to 
common anti-anaerobe antimicrobial agents. The prevalence of this species in preterm 
neonates may be not linked to a high degree of resistance to antimicrobial agents. This 
study provides new data on the genetic antibiotic resistance determinants of C. butyricum 
and reports for the first time the acquired resistance to tetracycline by ribosomal protection 
genes tet(O) and a potential mosaic tet(O/32/O) homologue. 
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Table 1 
Primers used for PCR and RT-PCR experiments 
Genes Primers Primer sequences (5’3’) 
tet(W), tet(M), tet(Q) tet1 
tet2 
GCTCAYGTTGAYGCAGGAA 
AGGATTTGGCGGSACTTCKA 
tet(O) OFF2 
OFR3 
TTGTTTTGGGGCTATTGGAG 
TATATGACTTTTGCAAGCTG 
tet(P) TetPCbutF 
TetPCbutR 
TTCTTGCTCATGTTGATGCC 
GAAGTATACTCAATATCAGC 
 TetP-ShrtF 
TetP-ShrtR 
GGCCCTGTTTCAACATTCAT 
ATCCACTTCCATGGGAACAA 
tet(K) TetKF 
TetKR 
GTACAAGGAGTAGGATCTGCTGCAT 
TTATTCCCCCTATTGAAGGACCTAA 
tet(L) TetLF 
TetLR 
TGAACGTCTCATTACCTGATATTGC 
TTTGGAATATAGCGAGCAAC 
erm(B) ErmBV 
ErmBR 
AATAAGTAAACAGGTTACGT 
CTACTGACAGCTTCCAAGGAGC 
 ErmBE5 
ErmBE6 
CTCAAAACTTTTTAACGAGTG 
CCTCCCGTTAAATAATAGATA 
erm(F) ErmF1 
ErmF2 
CGGGTCAGCACTTTACATTTG 
GGACCTACCTCATAGCAAG 
 ErmFS3 
ErmFS4 
GAGAGGAAAGAGAGACAATGTC 
TTTATCTACTCCGATAGCTTCC 
erm(Q) ErmQ3 
ErmQ4 
GGAGGAAATAAAATGATTATGAATGG 
CACATAAAGCTTCTGTTATATGACC 
lmrB LmrBF 
LmrBR 
GTTTTAGTACCAGTTACAGC 
CCAGAAGCAACTGCACTCCA 
 LmrB-ShrtF 
LmrB-ShrtR  
GCTTTAACTCCGGTAGCTGGT 
AGCCACTGTCTGTGATGGTG 
recA RecA-F 
RecA-R 
GCAGAGCATGCATTAGATCCT 
GAATCTCCCATTTCCCCTTC 
PCR, polymerase chain reaction; RT-PCR, reverse transcription PCR. 
Edited Table 1
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Table 2 
Susceptibility of Clostridium butyricum isolates to antimicrobials agents 
Antimicrobial agent No. of strains at an MIC (mg/L) of: MIC (mg/L) 
0.0625 0.125 0.250 0.5 1 2 4 8 16 32 64 128 256 MIC50 MIC90 
Penicillin G   7 12 8 7     6   1 64 
Amoxicillin  8 18 8     6     0.125 16 
Piperacillin    5 16 11 2    6   1 64 
Cefoxitin       12 18 10     8 16 
Imipenem   9 13 17 1        0.5 1 
Vancomycin    16 24         1 1 
Tetracycline 27 3     1 6 2 1    0.0625 8 
Tigecycline 30 3 5 1 1         0.0625 0.250 
Erythromycin    34 4        2 0.5 1 
Clindamycin        7 30 2  1  16 16 
Ofloxacin  1  2 33 4        1 1 
Metronidazole  6 23 11          0.125 0.5 
Chloramphenicol    5 32 3        1 1 
Linezolid    2 34 3 1       1 1 
MIC, minimal inhibitory concentration; MIC50/90, MICs for 50% and 90% of the organisms, respectively. 
Edited Table 2
